Search Results
Your search for ,tWO matches 12541 pages
Showing 11801 - 11850FDA Approves Netupitant and Palonosetron Combination Capsule for Chemotherapy-Induced Nausea and Vomiting
The U.S. Food and Drug Administration (FDA) today approved a combination of netupitant and palonosetron (Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy. The new drug, also known as NEPA, is a fixed-combination capsule comprised of two agents: oral palonosetron,...
Study Finds Potential Link Between BRCA1/2 Mutations and Salivary Gland Cancer
The risk of developing cancer in a salivary gland might be higher in people with BRCA1 or BRCA2 mutations, which are associated with breast and ovarian cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital...
New Predictive Model for Lung Cancer May Improve Accuracy in Prescreening Lung Nodules Prior to Resection
An investigative predictive model for lung cancer demonstrated more accuracy than the more commonly used Mayo Clinic model in prescreening lung nodules prior to resection, according to the results of a study reported by Deppen et al in the Journal of Thoracic Oncology. The investigators suggested...
Updated GEM2005 Trial Confirms Benefit of Melphalan/Bortezomib Combination in Elderly Multiple Myeloma Patients
Melphalan in combination with bortezomib (Velcade) should be maintained as one of the standards of care for the treatment of elderly patients with multiple myeloma, concluded Spanish trialists reporting updated results from the GEM2005 study comparing bortezomib/melphalan/prednisone with...
Anti–PD-1 Antibody Pembrolizumab Is Active in Ipilimumab-Refractory Advanced Melanoma
As reported in The Lancet by Robert et al, the anti–programmed-death receptor-1 (PD-1) antibody pembrolizumab (Keytruda) produced durable responses in a phase I trial in patients with ipilimumab (Yervoy)-refractory melanoma. The study provided the basis for the recent accelerated approval of...
One in Three People With Cancer Has Anxiety or Other Mental Health Challenges
Researchers in Germany report that nearly one-third of more than 2,100 patients with cancer interviewed at inpatient and outpatient care centers experienced a clinically meaningful level of mental or emotional distress that meets the strict diagnostic criteria for mental disorders including...
Overexpression of Threonyl tRNA-Synthetase Demonstrates Potential Value as a Prognostic and Therapeutic Factor in Ovarian Cancer Patients
The molecule threonyl tRNA-synthetase may provide value as a serum diagnostic marker and a potential target of therapy for ovarian cancer, according to the results of a study reported by Wellman et al in BMC Cancer. In addition, the mortality risk was slightly reduced for patients with high...
Adjuvant Radiotherapy Benefits Survival in Subsets of Patients With Node-Positive Prostate Cancer
In an analysis of outcomes in patients with node-positive prostate cancer reported in the Journal of Clinical Oncology, Abdollah et al found that adjuvant radiotherapy is associated with a survival benefit in patients with low-volume nodal disease in the setting of intermediate- to high-grade...
2014 Nobel Prize in Physiology or Medicine Awarded to John O’Keefe, FRS, May-Britt Moser, PhD, and Edvard I. Moser, PhD
The Nobel Assembly at Karolinska Institutet has awarded the 2014 Nobel Prize in Physiology or Medicine to John O’Keefe, FRS, and to May-Britt Moser, PhD, and Edvard I. Moser, PhD, for their discoveries of cells that constitute a positioning system in the brain. This “inner GPS”...
Enhanced Benefit Shown With FOLFIRI/Ziv-Aflibercept in Subset of Patients With Metastatic Colorectal Cancer
The survival benefit demonstrated in the VELOUR study for FOLFIRI (irinotecan, fluorouracil [5-FU], leucovorin) plus ziv-aflibercept (Zaltrap) vs FOLFIRI plus placebo in metastatic colorectal cancer patients who had disease progression on oxaliplatin-based chemotherapy persisted beyond median...
FDA Grants Breakthrough Therapy Designation to AP26113 for ALK-Positive NSCLC
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Ariad Pharmaceutical’s investigational agent AP26113 for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC) who are resistant to crizotinib...
ESMO 2014: Everolimus Improves Overall Survival in Patients With Advanced Pancreatic Neuroendocrine Tumors
In a phase III trial, treatment with everolimus (Afinitor) resulted in a median overall survival of over 3 and a half years in patients with well-differentiated and progressive pancreatic neuroendocrine tumors, representing what the study authors called a "clinically important" although not...
ESMO 2014: BRAF/MEK Inhibitor Combinations Impressive in Melanoma Trials
For advanced/metastatic melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to studies presented at the ESMO 2014 Congress that demonstrated improved progression-free and overall survival for regimens combining a BRAF inhibitor with an inhibitor of the...
Study Finds Association Between Increased Esophageal COX-2 Expression and Barrett’s Esophagus, Obesity, and Smoking
Elevated esophageal mucosa cyclooxygenase-2 (COX-2) levels appear to be associated with the presence of Barrett’s esophagus as well as high waist-to-hip ratios and current tobacco smoking, according to the results of a study reported by Nguyen et al in Digestive Diseases & Sciences. These ...
ESMO 2014: Adding Cediranib to Chemotherapy Improves Progression-Free Survival in Metastatic or Recurrent Cervical Cancer
For patients with recurrent or metastatic cervical cancer, adding the experimental drug cediranib to standard chemotherapy improved tumor shrinkage and resulted in a modest improvement in progression-free survival, researchers reported at the ESMO 2014 Congress in Madrid (Abstract LBA25_PR). In...
ESMO 2014: Afatinib Improves Progression-Free Survival in Advanced Head and Neck Cancer
The tyrosine kinase inhibitor afatinib (Gilotrif) was significantly superior to methotrexate as second-line therapy in patients with advanced squamous cell carcinoma of the head and neck who progressed after platinum-based chemotherapy, according to results of the LUX-Head & Neck 1 trial. The...
ESMO 2014: Novel Oral Agent Treats Cancer-Related Cachexia in Non–Small Cell Lung Cancer
For the first time, studies show that a drug is effective in treating cancer-related cachexia. Oral anamorelin hydrochloride increased lean body mass, achieved weight gain, and improved quality of life in patients with cancer-related cachexia in two pivotal phase III studies presented at the ESMO...
Aldoxorubicin Receives FDA Orphan Drug Designations for Glioblastoma, Small Cell Lung Cancer, and Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designations to aldoxorubicin in three indications: glioblastoma multiforme, small cell lung cancer, and ovarian cancer. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and...
Subclinical Peripheral Neuropathy Is Common in Treatment-Naive Multiple Myeloma Patients, Correlates With Decreased Fingertip Innervation Density
In a study reported in the Journal of Clinical Oncology, Kosturakis et al found that the majority of patients with multiple myeloma had subclinical peripheral neuropathy prior to chemotherapy and that deficits corresponded with decreased fingertip innervation density. Study Details In the study,...
Screening for and Treating Early-Stage Lung Cancer Is Less Costly Than Treating Late-Stage Disease
A new study found that the average cost to screen high-risk individuals for lung cancer with low-dose computed tomography (CT) plus the average cost of curative-intent treatment is lower than the average cost to treat advanced-stage lung cancer, which quite rarely results in a cure. The findings by ...
New ALK Inhibitor Alectinib Shows Activity vs Crizotinib-Resistant NSCLC
In the phase I portion of a phase I/II study reported in The Lancet Oncology, Gadgeel et al found that the novel ALK inhibitor alectinib showed activity against systemic disease and brain metastases in patients with non–small cell lung cancer (NSCLC) resistant to the ALK inhibitor crizotinib...
Soy Intake May Adversely Affect Gene Expression in Early Breast Cancer
In a randomized study reported in the Journal of the National Cancer Institute, Shike et al found that soy supplementation resulting in high genistein levels was associated with overexpression of the tumorigenic growth factor receptor FGFR2 and genes that drive cell cycle and proliferation...
Meta-Analysis Shows No Overall Survival Benefit of Six vs Fewer Planned Cycles of First-Line Platinum-Based Chemotherapy in Advanced NSCLC
In a systematic review and meta-analysis of individual patient data reported in The Lancet Oncology, Rossi et al found no overall survival benefit with six vs fewer than six planned cycles of first-line platinum-based treatment in patients with advanced non–small cell lung cancer (NSCLC). A...
FDA Grants Orphan Drug Designation to Bivalent Vaccine for Neuroblastoma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MabVax Therapeutics’ vaccine for the treatment of relapsed or recurrent high-risk neuroblastoma in remission or with limited residual disease after best available treatment. The bivalent vaccine is intended to...
Clinical Trials Investigate Treatment Options for Precursor Diseases to Multiple Myeloma
The availability of newer agents that have transformed treatment outcomes in multiple myeloma has naturally led to interest in studying these drugs earlier in precursor states, such as monoclonal gammopathy of undetermined significance and smoldering myeloma. Recent evidence suggests that this may...
Pilot Study Evaluates Concurrent Use of Sunitinib and Radiation Therapy in Recurrent High-Grade Glioma
The combination of continuous daily-dosed sunitinib (Sutent) and hypofractionated stereotactic radiation therapy produced acceptable toxicity and “encouraging” 6-month progression-free survival in previously irradiated patients with recurrent high-grade glioma, according to the results...
Adding Pan-Deacetylase Inhibitor Panobinostat to Bortezomib and Dexamethasone Improves Progression-Free Survival in Relapsed Myeloma
In the phase III PANORAMA1 trial reported in The Lancet Oncology, San-Miguel and colleagues found that adding the pan-deacetylase inhibitor panobinostat to bortezomib (Velcade) and dexamethasone improved progression-free survival in patients with relapsed or relapsed and refractory multiple...
Search for Effective Regimens in Elderly Patients With Hodgkin Lymphoma
As the U.S. population continues to age, oncologists will be faced with a growing number of elderly patients with Hodgkin lymphoma, but there is currently no consensus on how to treat this population. Regimens used to treat younger patients have too much toxicity for most older patients, and thus...
SMaRT Oncology-3 Trial Reports Collaborative Care Program Reduces Major Depression in Patients With Lung Cancer
In the SMaRT Oncology-3 study reported in The Lancet Oncology, Walker et al found that an integrated collaborative treatment program for depression (‘depression care for people with cancer’) was associated with significantly reduced severity of depression compared with usual care in...
mTOR Inhibitor Ridaforolimus Shows Activity in Advanced Endometrial Cancer
The oral mTOR inhibitor ridaforolimus was modestly active and reasonably tolerated in women with recurrent or metastatic endometrial cancer, according to the results of a phase II study reported in Gynecologic Oncology. Tsoref et al suggested that it may prove to be an effective therapeutic...
Long-Term Colorectal Cancer Mortality After Removal of Adenomas
There are few data available on long-term risk of colorectal cancer mortality after adenoma removal. In a Norwegian study reported in The New England Journal of Medicine, Løberg et al found that patients who had low-risk adenomas removed had lower colorectal cancer mortality risk and those...
ASTRO: Long-Term Androgen-Deprivation Therapy Plus High-Dose Radiation Therapy Improves Biochemical Control and Survival Rates in Prostate Cancer
Prostate cancer patients who receive high-dose radiation therapy followed by a longer period of androgen-deprivation therapy have higher 5-year biochemical disease–free survival and overall survival rates compared to patients who receive high-dose radiation therapy and a shorter duration of...
Study Identifies Two Novel ALK Mutations Causing Lung Cancer Resistance to ALK Inhibitors
In a recent study investigating alectinib resistance in ALK-positive lung cancers, researchers identified two novel ALK mutations that are sensitive to ceritinib (Zykadia), a next-generation ALK tyrosine kinase inhibitor approved by the FDA earlier this year for advanced non–small cell lung...
Anti-CD19 CAR T-Cell Treatment Effective in Chemotherapy-Refractory B-Cell Malignancies
In a study reported in the Journal of Clinical Oncology, Kochenderfer et al found that single infusions of autologous T cells expressing an anti-CD19 chimeric antigen receptor (CAR) produced responses in nearly all patients with chemotherapy-refractory CD19-positive B-cell malignancies, including...
AACR’s 2014 Cancer Progress Report Stresses Research Advances and More Federal Funding
The American Association for Cancer Research (AACR) released its 2014 Cancer Progress Report today, which highlights the quickening pace of drug development and approval, especially in molecularly targeted agents that are leading to increased numbers of cancer survivors. However, the report also...
ASTRO: Pretreatment Serum Levels of VEGF-A and TGF-β1 Predictive of Outcomes in Esophageal Cancer
Serum levels of VEGF-A and TGF-β1 may be helpful in tailoring neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma, according to research presented at the American Society for Radiation Oncology’s (ASTRO) 56th Annual Meeting (Abstract 10). Results of...
ASTRO: Radiation Therapy Alone vs Chemoradiotherapy for Reducing Dysphagia in Advanced Esophageal Cancer
Radiation therapy alone is as effective in decreasing swallowing complications experienced by advanced esophageal cancer patients as radiation therapy combined with chemotherapy, thus allowing patients to forgo chemotherapy, according to research presented at the American Society for Radiation...
ASTRO: Shorter Course of Androgen-Deprivation Therapy Yields Improved Quality of Life for High-Risk Prostate Cancer Patients
Patients with high-risk prostate cancer who received radiation therapy and an 18-month course of androgen-deprivation therapy recovered a normal testosterone level in a shorter amount of time compared to those who received a 36-month course of androgen-deprivation therapy. The shorter course of...
No Significant Progression-Free Survival Benefit of Adding Ramucirumab to First-Line Docetaxel in Advanced HER2-Negative Breast Cancer
In the phase III ROSE/TRIO-12 trial, reported in the Journal of Clinical Oncology, Mackey et al found no significant improvement in investigator-assessed progression-free survival by adding the antiangiogenic VEGFR-2 inhibitor ramucirumab (Cyramza) to first-line docetaxel in women with...
Increased Risk of Melanoma in Flight-Based Occupations
Airline pilots and cabin crew are occupationally exposed to higher levels of cosmic and ultraviolet radiation. In a meta-analysis reported in JAMA Dermatology, Sanlorenzo et al found that these people have a more than twofold greater risk of melanoma compared with the general population. Increased ...
FDA Approves New Indication for Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
The U.S. Food and Drug Administration (FDA) has approved a new indication for the use of enzalutamide (Xtandi) capsules to treat patients with metastatic castration-resistant prostate cancer. The new indication is for men with metastatic castration-resistant prostate cancer who have not received...
No Benefit of Adding Cetuximab to Cisplatin and Accelerated Radiotherapy in Stage III or IV Head and Neck Carcinoma
Use of cisplatin or cetuximab (Erbitux) with radiotherapy improves overall survival in stage III or IV head and neck carcinoma, and adding cetuximab to platinum therapy improves overall survival in metastatic disease. In the phase III Radiation Therapy Oncology Group (RTOG) 0522 trial reported in...
Radiation Therapy With Concurrent Chemotherapy After Surgery Is an Effective Treatment for High-Risk Endometrial Cancer
Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for high-risk endometrial cancer, according to a study reported by Cho et al in the International Journal of Radiation Oncology • Biology • Physics Endometrial...
Olaparib Tablet Found Safe and Effective in Heavily Pretreated Patients With Ovarian Cancer
A phase Ib clinical trial of the tablet form of olaparib, a PARP inhibitor, in combination with paclitaxel and carboplatin chemotherapy in heavily pretreated patients with advanced-stage ovarian cancer finds the drug to be safe and effective, especially in those women with BRCA gene mutations. The...
No Significant Difference in Time to Treatment Failure With Rituximab Retreatment vs Maintenance in Low-Tumor-Burden Follicular Lymphoma
Maintenance rituximab (Rituxan) has been shown to improve progression-free survival vs observation in low-tumor-burden follicular lymphoma. In the Eastern Cooperative Oncology Group (ECOG) E4402 Trial (RESORT), reported in the Journal of Clinical Oncology, Kahl et al found no significant difference ...
Breast-Conserving Therapy Shows Survival Benefit Over Mastectomy in Patients With Early-Stage Hormone Receptor–Positive Disease
When factoring in what is now known about breast cancer biology and heterogeneity, breast-conserving therapy may offer a greater survival benefit over mastectomy to women with early-stage, hormone receptor–positive disease, according to research from The University of Texas MD Anderson Cancer ...
Study Finds No Link Between Wearing a Bra and Breast Cancer
Despite conjecture in the lay media that wearing a bra may be a risk factor for breast cancer based on the potential for bras to interfere with lymph circulation and drainage, hampering the removal of waste and toxins, there were few scientific studies investigating the issue. Now, a new study by...
Survey Reveals Factors Influencing Women’s Consideration of Contralateral Prophylactic Mastectomy
A survey of 150 women newly diagnosed with breast cancer provides new insight into factors that influence women’s decisions to undergo contralateral prophylactic mastectomy. This is one of the first studies to look at women’s breast surgery preferences prospectively, before they undergo ...
Breast Cancer Surgery and Reconstruction Complications Are Rare, but Risk of Some Complications Higher With Bilateral vs Unilateral Mastectomy
A new analysis of 30-day post-surgery complications among more than 18,000 women with breast cancer undergoing bilateral and unilateral mastectomy with breast reconstruction found that complications were generally rare for either type of surgery, with an overall rate of complications of 5.3%....
Family Physician–Signed Reminder Letters Improve Return Rates for Women Overdue for Screening Mammography
A large study conducted through the BC Cancer Agency in British Columbia, Canada, reports that adding family physician–signed reminder letters to the standard schedule of postcard reminders substantially improves return rates for screening among women who are overdue for such screening. In a...
